

FEE TRANSMITTAL

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT	\$180
-------------------------	-------

Complete if Known	
Application Number	10/042,761
Filing Date	January 15, 2003
First Named Inventor	A.G. Daifotis et al.
Examiner Name	To be determined
Group Art Unit	To be determined
Attorney Docket Number	20002YPCI

METHOD OF PAYMENT (Check one)

Deposit Account

Deposit Account Number

13-2755

Deposit Account Name

Merck & Co., Inc.

The Director is authorized to:

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	750	Utility filing fee	
1002	330	Design filing fee	
1004	750	Reissue filing fee	
1005	160	Provisional filing fee	
SUBTOTAL(1)			\$0

2. EXTRA CLAIM FEES

		Extra	Fee from below	Fee Paid
Total Claims		20	** = 0	x \$18 = 0
Independent Claims		3	** = 0	x \$84 = 0
Multiple Dependent Claims				\$280 =

** or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code	Fee (\$)	Fee Description
1202	18	Claims in excess of 20
1201	84	Independent claims in excess of 3
1203	280	Multiple dependent claim, if not paid
1204	84	**Reissue independent claims over original patent
1205	18	**Reissue claims in excess of 20 and over original patent
SUBTOTAL(2)		

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Fee Code	Large Entity Fee (\$)	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	
1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1251	110	Extension for reply within first month	
1252	410	Extension for reply within second month	
1253	930	Extension for reply within third month	
1254	1,450	Extension for reply within fourth month	
1255	1,970	Extension for reply within fifth month	
1401	320	Notice of Appeal	
1402	320	Filing a brief in support of an appeal	
1403	280	Request for oral hearing	
1452	110	Petition to revive - unavoidable	
1453	1,300	Petition to revive - unintentional	
1501	1,300	Utility issue fee (or reissue)	
1502	470	Design issue fee	
1460	130	Petitions to the Commissioner	
1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	Submission of Information Disclosure Statement	180
8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	Request for Continued Examination (RCE)	
Other fee (specify) _____			
Other fee (specify) _____			
SUBTOTAL(3)			\$180

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	J. Antonio Garcia-Rivas	Reg. Number	42,567
Signature		Date	8/14/03

IN DUPLICATE


Application Number: 10/042,761
Filing Date: 01/15/2003
First Named Inventor: A.G. Daifotis et al.
Group Art Unit: To be determined
Examiner Name: To be determined
Attorney Docket Number: 20002YPCI

FIRST CLASS MAIL CERTIFICATE

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450, ON THE DATE APPEARING BELOW.

MERCK & CO., INC.

MAILED BY Barbara Muller DATE 8-14-03



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: A.G. DAIFOTIS et al.

Serial No. 10/042,761

Filed: January 15, 2003

For: METHOD FOR INHIBITING BONE
RESORPTIONArt Unit: To be determinedExaminer: To be determined

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

08/20/2003 JADDO1 00000051 132755 10042761
01 FC:1806 180.00 DA

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Barbara Muller Date 8-14-03



INFORMATION DISCLOSURE STATEMENT

4. Except for Cite Nos. 96-116 _____, copies of the references listed on the attached form are not enclosed

because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
09/376,315	August 18, 1999	20002YPCB

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- the attached information is filed within three months of the filing date of the captioned case.
- the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,


By: J. Antonio Garcia-Rivas
Attorney _____ For Applicant(s)
Reg. No. 42,567 _____
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-1513 _____
Date: August 14, 2003



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/042,761
				Filing Date	January 15, 2003
				First Named Inventor	A.G. Daifotis
				Group Art Unit	To be determined
				Examiner Name	To be determined
Sheet	1	of	8	Attorney Docket Number	20002YPCI

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
1	5,270,365			Gertz et al.	12/14/1993
2	5,366,965			Strein	11/22/1994
3	4,761,406			Flora et al.	08/02/1988
4	4,425,339			Pitchford	01/10/1984
5	4,621,077			Rosini et al.	11/04/1986
22	5,616,560			Geddes	04/01/1997
23	5,780,455			Brenner et al.	07/14/1998
24	5,773,429			Fuisz	06/30/1998
27	5,488,041			Barbier et al.	01/30/1996
28	4,980,171			Fels et al.	12/15/1990
40	4,812,304			Anderson et al.	03/14/1989
41	4,822,609			Flora	04/18/1989
48	5,358,941			Bechard et al.	10/25/1994
49	5,616,571			Daifotis et al.	04/01/1997
50	5,853,759			Katdare et al.	12/29/1998
51	5,804,570			Santora II et al.	09/08/1998
58	5,583,122			Benedict et al.	12/10/1996
59	5,622,721			Dansereau et al.	04/22/1997
60	4,927,814			Gall et al.	05/22/1990
63	5,994,329			Daifotis et al.	11/30/1999

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
6		WO 95/30421		Goodship et al.	11/16/1995
7		WO 96/17616		Gazard	06/13/1996
8		WO 94/00129		Francis et al.	01/06/1994
9		WO 94/00130		Hovancik et al.	01/06/1994
10		WO 94/21242		D'Souza et al.	09/29/1994
25		WO 95/28145		Shinoda et al.	10/26/1995
26		EP 0 600 834 A1		Goodship et al.	08/06/1994
37		EP 0 274 158		Ebetino et al.	07/13/1988
38		WO 95/08331		Bechard	03/30/1995
39		WO 95/28936		Yates	11/02/199

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003



U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
66		WO 96/25166			Merck & Co., Inc.	08/22/1996
67		WO 93/11786			Procter & Gamble Pharm., Inc.	06/24/1993
96		HU P9602888			Merck & Co., Inc.	03/28/1997
97		HU P9403762			Procter & Gamble Pharm., Inc.	09/28/1995
98		WO 96/38156			Merck & Co., Inc.	12/05/1996
116		EP 0128 736 A1			Yamanouchi Pharm. Co. Ltd.	12/19/1984

Examiner Initials Reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of page(s) cited.

Examiner: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/042,761
				Filing Date	January 15, 2003
				First Named Inventor	A.G. Daifotis
				Group Art Unit	To be determined
				Examiner Name	To be determined
				Attorney Docket Number	20002YPC1

3 of 8


OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	11	Lunar News, April 1997, "Update: Bisphosphonate", pp. 30-32
	12	Gertz et al., Osteoporosis Int. (1993), Suppl. 3: S13-16, "Clinical pharmacology of alendronate sodium"
	13	Gertz et al., Clin. Pharma. Ther. (1995), Vol. 58, pp. 288-98, "Studies of the oral bioavailability of alendronate"
	14	de Vernejoul et al., Calcified Tissue Int'l, Vol. 40 (1987), pp. 160-165, "Different schedules of administration of (3 amino-1-hydroxypropylidene)-1,1-bisphosphonate induce different changes ..."
	15	Lufkin et al., Osteoporosis Int'l. (1994), Vol. 4, pp. 320-322, "Pamidronate: An unrecognized problem in gastrointestinal tolerability".
	16	De Groen et al., N. England J. of Medicine, (1996), Vol. 335, pp. 1016-1021, "Esophagitis associated with the use of alendronate"
	17	Castell, (an editorial), N. England J. of Medicine (1996), Vol. 335, pp. 1058-1059, "Pill esophagitis - the case of alendronate".
	18	Liberman et al., (correspondence), N. England J. of Medicine (1996), Vol. 335, pp. 1069-1070, "Esophagitis and alendronate".
	19	Chesnut et al., Am. J. of Medicine, Vol. 99 (1995), pp. 144-152, "Alendronate treatment of the postmenopausal osteoporotic woman ...".
	20	Cassidy et al., Digestive Diseases and Sciences, Vol. 37 (1992), pp. 1206-1211, "Continuous verus intermittent acid exposure in production of esophagitis in feline model".
	21	Mortensen et al., J. of Bone & Mineral Res., (1995) Vol. 10, suppl. 1, p. s140, "Prevention of early postmenopausal bone loss of risendronate".
	29	Singer et al., Advances in Endocrin.& Metab., Vol. 6 (1995), pp. 259-288, "Bisphosphonates in the treatment of disorders or mineral metabolism".
	30	Lieberman et al., N. Eng. J. of Medicine, Vol. 333 (1995), pp. 1437-1443, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis".
	31	Bankhurst et al., Arthritis and Rheumatism, Vol. 38, No. 9, Suppl. 1 (1995), S359, "Three-year treatment with alendronate prevents fractures in women with postmenopausal osteoporosis".
	32	Filipponi et al., J. of Bone & Min. Research, Vol. 10 (1995), pp. 697-703, "Cyclical clondronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy".

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

8

COMPLETE IF KNOWN	
Application Number	10/042,761
Filing Date	January 15, 2003
First Named Inventor	A.G. Daifotis
Group Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	20002YPCI

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	33	McClung et al., Bone, Vol. 17 (1995), pp. 493S-496S, "Tiludronate therapy for Paget's disease of bone".
	34	Seltenmeyer et al., Bone (NY), Vol. 20, No. 4, Suppl., (1997) pp. 114S, "A comparison of the antiresorptive potency of various bisphosphonates in vivo with their inhibitory effect in vitro on squalene synthase and cellular sterol synthesis".
	35	Adachi et al., Today's Therapeutic Trends, Vol. 14, No. 1 (1996), pp. 13-24, "Osteoporosis -- its diagnosis, management and treatment with a new oral bisphosphonate agent, etidronate".
	36	Bell et al., Endocrine, Vol. 6(2) (1997), pp. 203-206, "Bisphosphonates in the Treatment of Osteoporosis".
	42	Melsen et al., Osteoporosis, Chapt. 60(1996), pp. 1145-1158, "ADFR - The Concept and its performance".
	43	Thompson et al., J. of Bone & Min. Research, Vol. 7(1992), pp. 951-960, "The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons".
	44	Balena et al., J. Clin. Invest., Vol. 92 (1993), pp. 2577-2586, "The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates".
	45	Peter et al., Digestive Diseases & Sciences, Vol. 43 (1998), pp. 1009-1015, "Comparative study of potential for bisphosphonates to damage gastric mucosa of rats".
	46	Peter et al., Digestive Diseases & Sciences, Vol. 43 (1998), pp. 1998-2002, "Esophageal irritation due to alendronate sodium tablets".
	47	Harris et al., J. of Clin. Endoc. & Metab., 76:1399-1406 (1993), "The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone...".
	52	Khan et al., Bone, Vol. 20 (1997), pp. 263-271, "Alendronate in the treatment of Paget's disease of bone".
	53	Physician's Desk Reference, 51st ed. (1997), pp. 1703-1706, "Fosamax".
	54	Gertz et al., J. of Bone & Min. Res., Vol. 9 (1994), pp 135-142, "Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine".
	55	Fleisch, J. of Clin. Endoc. & Metab., Vol. 76 (1993), pp. 1397-1398, "Editorial: Prospective use of bisphosphonates in osteoporosis".
	56	Chesnut et al., Osteoporosis Int'l (1993), Suppl. 3: S17-19, "Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women".

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

AUG

8 2003

Sheet

5

of

8

Attorney Docket Number

COMPLETE IF KNOWN

Application Number	10/042,761
Filing Date	January 15, 2003
First Named Inventor	A.G. Daifotis
Group Art Unit	To be determined
Examiner Name	To be determined

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	57	Gertz et al., J. of Bone & Min. Res., Vol. 6, Suppl. 1 (1991), Abstract No. 790, p. S281, "Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidene bisphosphonate) in postmenopausal women".
	61	Mortensen et al., J. Bone & Min. Res., (1995), 10 (Supp. 1): S360, "Prevention of early postmenopausal bone loss by residronate: A two year study".
	62	Actonel™ (risedronate sodium tablets) package insert, dated March 1998.
	68	Lunar News (July 1996), "Update: Bisphosphonate", pp. 23-24
	69	Lunar News (April 1996), "Update: Bisphosphonate", p. 31
	70	The Pink Sheet (Dec. 18, 1995), Vol. 57, Issue 51, "Merck Cozaar generating 25,000 scripts weekly after six months on market; Foxamax off to quick start, company tells securities analyst meeting".
	71	Scrip (11/24/99), "Merck develops once-weekly Fosamax".
	72	Baran, Geriatrics, Vol. 56, No. 3 (March 2001), pp. 28-32, "Osteoporosis: Efficacy and safety of a bisphosphonate dosed once weekly".
	73	Bone et al., Clinical Therapeutics, Vol. 22, No. 1 (2000), pp. 15-28, "Weekly administration of alendronate: Rationale and plan for clinical assessment".
	74	Fleisch, Expert Opinion Therapeutic Patents, Vol. 11, No. 9 (2000), p. 1371-1381, "Bisphosphonates: mechanisms of action".
	75	Peter et al., Journal of Pharmacology & Experimental Therapeutics, Vol. 276, No. 1 (1996), p. 271-276, "Long-term safety of the aminobisphosphonate alendronate in adult dogs".
	76	Rodan et al., Osteoporosis International (1993) Suppl., 3:S7-12, "Preclinical Pharmacology of alendronate".
	77	Schnitzer, Expert Opinion Pharmacother., Vol. 2, No. 9 (2001), pp. 1461-1472, "Update on alendronate for osteoporosis: once-weekly dosing".
	78	Schnitzer et al., Aging: Clinical and Experimental Research, Vol. 12, No. 1 (2000), P. 1-12, "Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis".
	79	Seedor et al., Journal of Bone & Mineral Research, Vol. 6, No. 4 (1991), pp. 339-346, "The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats".

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003




<p style="margin: 0;">Substitute for form 1449A/PTO</p> <p style="margin: 0;">INFORMATION DISCLOSURE</p> <p style="margin: 0; font-weight: bold;">STATEMENT BY APPLICANT</p> <p style="margin: 0; font-style: italic;">(use as many sheets as necessary)</p>				COMPLETE IF KNOWN	
				Application Number	10/042,761
				Filing Date	January 15, 2003
				First Named Inventor	A.G. Daifotis
				Group Art Unit	To be determined
				Examiner Name	To be determined
Sheet	6	of	8	Attorney Docket Number	
20002YPCI					

OTHER NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
	80	Sorrentino, Endoscopy, Vol. 28 (1996), p. 529, "Esophageal ulceration due to alendronate".			
	81	Blank, American College of Gastroenterology 66th Annual Scientific Meeting, "Lack of gastric adaptation to weekly versus daily alendronate administration in rats".			
	82	Bone et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M392, "Once-weekly alendronate: Two year subgroup efficacy analyses in postmenopausal women with osteoporosis".			
	83	Bone III et al., 6th International Symposium on Clinical Disorders of Bone and Mineral Metabolism, Venice, Italy, November 20-25, 1999, "Alendronate 70 mg once weekly is therapeutically equivalent to alendronate in 10 mg daily".			
	84	Brown et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M402, "Efficacy, safety and tolerability of once weekly (80 mg vs. 160 mg) oral alendronate in postmenopausal osteoporosis".			
	85	Delaney et al., ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract, P1-469 (June 2001), p. 249, "Bone density changes in response to risedronate once weekly".			
	86	Gordon et al., ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract, P1-460 (June 2001), p. 247, "Weekly administration of risedronate increase bone mineral density".			
	87	Lindsay et al., Arthritis & Rheumatism, Vo. 44, No. 9 (Suppl.), Abstract No. 604, "Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women".			
	88	Rizzoli et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M401, "Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis".			
	89	Rizzoli et al., Annals of the Rheumatic Diseases, Annual European Congress of Rheumatology, EULAR 2001, Prague, Czech Republic, Vol. 60, Suppl. 1 (July 2001), Abstract SAT0164, p. 256, "Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis".			
	90	Van Dyke, et al., Annals of the Rheumatic Diseases, Annual European Congress of Rheumatology, EULAR 2001, Prague, Czech Republic, Vol. 60, Suppl. 1 (July 2001), Abstract SAT0167, p. 256, "Safety of once-weekly alendronate 70 mg in periodontal disease".			
	91	Wimalawansa, Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), Abstract SA352, "Once a week alendronate therapy: A convenient and effective way of prevention and treatment of osteoporosis: A four-year clinical study".			
	92	Wimalawansa, Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), Abstract SU399, "Efficacy of once a week risedronate in comparison with once-weekly alendronate therapy for postmenopausal osteoporosis: One-year data".			
	93	Wimalawansa, ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract P1-438, p. 241-242, "Highly efficacious and cost-effective alendronate regimen for postmenopausal osteoporosis: A four-year clinical study"			
	94	Woodson, Osteoporosis International, Vol. 11, Suppl. 2 (2000), Chicago, Illinois, p. S204, Abstract 550 (514), "Once weekly risedronate therapy".			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003

 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i></p>				COMPLETE IF KNOWN	
Sheet	7	of	8	Application Number	10/042,761
				Filing Date	January 15, 2003
				First Named Inventor	A.G. Daifotis
				Group Art Unit	To be determined
				Examiner Name	To be determined
				Attorney Docket Number	20002YPCI

OTHER NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
	99	Men's Osteoporosis Support Group, Vol. 1, Issue 2, 1 July 1997			
	100	Rote List 1997, 66 023 (Fosamax)			
	101	Reddy M.S. et al, J. Periodontol, 1995, Vol. 66(3), pp. 211-217, "Alendronate Treatment of Naturally-Occurring Periodontitis in Beagle Dogs".			
	102	Fleisch H., "Bisphosphonates in Bone Disease from the Laboratory to the patient", 1995 (Book)			
	103	Black D.M. et al., The Lancet, 1996, 348, pp. 1535-1541, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures".			
	104	Affidavit of Gideon Rodan from validity trial of IL 94612 dated 17 Nov. 2000			
	105	Merck & Co., Inc. - Instructions for Once Weekly Fosamax, January 2001			
	106	Lombardi et al., Ann. Ital. Med. Int. 7, 1992, 3 Suppl., pp. 158-165, "Clinical trials with bisphosphonates"			
	108	Reid et al, American Journal of Medicine, 1996, Vol. 101, pp. 341-348, "Biochemical and Radiologic Improvement in Paget's Disease of Bone Treated with Alendronate: A Randomized, Placebo-controlled Trial".			
	109	Passeri et al, Bone and Mineral, 1991, Vol. 15, pp. 237-248, "Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis".			
	110	Devogelaer et al, Bone, 1996, Vol. 18(2), pp. 141-150, "Oral Alendronate Induces Progressive Increases in Bone Mass of the Spine, Hip, and Total Body Over 3 Years in Postmenopausal Women with Osteoporosis".			
	111	Siris et al, J. Clin. Endo. Metab., 1996, Vol. 81(3), pp. 961-967, "Comparative Study of Alendronate Versus Etidronate for the Treatment of Paget's Disease of Bone".			
	112	Toolan et al, J. Bone Min. Res., 1992, Vol. 3, pp. 1399-1406, "Effects of 4-Amino-1-Hydroxybutylidene Bisphosphonate on Bone Biomechanics in Rats".			
	113	Balena et al, Bone, 1993, Vol. 14, pp. 499-504, "the Aminobisphosphonate Alendronate Inhibits Bone Loss Induced by Thyroid Hormone in the Rat Comparison Between Effects on Tibiae and Vertebrae".			
	114	Fleisch et al, Hormone and Metabolic Research, Vol. 29 (1997), pp. 145-150, "Bisphosphonates: Mechanisms of Action and Clinical Use in Osteoporosis - An Update".			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003



Substitute for form 1449A/PTO		<i>COMPLETE IF KNOWN</i>		
INFORMATION DISCLOSURE		Application Number	10/042,761	
STATEMENT BY APPLICANT		Filing Date	January 15, 2003	
AUG 18 2003 <i>(use as many sheets as necessary)</i>		First Named Inventor	A.G. Daifotis	
		Group Art Unit	To be determined	
		Examiner Name	To be determined	
8	of	8	Attorney Docket Number	20002YPCI

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003